How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Omics Based Clinical Trials Market
- By Omics Technology: Genomics, Proteomics, Metabolomics, Transcriptomics, Epigenomics
- By Clinical Trial Phase: Phase I, Phase II, Phase III, Phase IV
- By Application Area: Oncology, Cardiovascular Diseases, Neurological Disorders, Infectious Diseases, Rare Diseases
- By End User: Pharmaceutical Companies, Biotechnology Firms, Contract Research Organizations (CROs), Academic and Research Institutes, Hospitals and Clinics
- By Study Design: Observational Studies, Interventional Studies, Biomarker Discovery Studies, Pharmacogenomics Studies
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Genomics leads By Omics Technology at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 303 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.182 →
- 12 Company Profiles 16 players: SWOT & benchmarking p.190 →
Full report · locked preview
Everything inside the Omics Based Clinical Trials Market report
A complete, evidence-based study - 12 chapters and 127 sections covering market size, segmentation across 5 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Omics Technology 5
Clinical Trial Phase 4
Application Area 5
End User 5
Study Design 4
Companies profiled
Thermo Fisher Scientific
Illumina Inc.
QIAGEN N.V.
Agilent Technologies Inc.
Bio-Rad Laboratories Inc.
PerkinElmer Inc.
Roche Diagnostics
BGI Genomics
Sartorius AG
Danaher Corporation
Oxford Nanopore Technologies
GenScript Biotech Corporation
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Thermo Fisher Scientific
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Illumina Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →QIAGEN N.V.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Agilent Technologies Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Bio-Rad Laboratories Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →PerkinElmer Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Roche Diagnostics
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →BGI Genomics
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Sartorius AG
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Danaher Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Oxford Nanopore Technologies
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →GenScript Biotech Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Novogene Corporation
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →F. Hoffmann-La Roche Ltd
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Charles River Laboratories International
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$3,637M by 2033 · 6.7% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Genomics37.3
- Proteomics10.0
- Metabolomics25.8
- Transcriptomics12.5
- Epigenomics14.5
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$713.2M → $1,087M · 5.4%
Europe$497.1M → $938.4M · 8.3%
Asia Pacific$453.9M → $840.9M · 8.0%
Latin America$281.0M → $500.0M · 7.5%
Middle East and Africa$216.1M → $329.2M · 5.4%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →6.672026
6.692027
6.712028
6.712029
6.722030
6.742031
6.752032
6.762033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Thermo Fisher Scientific20.4
- Illumina Inc.14.4
- QIAGEN N.V.9.7
- Agilent Technologies Inc.9.4
- Bio-Rad Laboratories Inc.10.2
- PerkinElmer Inc.7.8
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Omics Technology26.2%
Clinical Trial Phase34.5%
Application Area11.8%
End User10.6%
Study Design16.9%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America29.4
- Europe25.4
- Asia Pacific22.8
- Latin America13.5
- Middle East and Africa8.9
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Thermo Fisher Scientific | 87 | 74 | 74 | 96 | 78 | 96 | 84 |
| Illumina Inc. | 76 | 82 | 77 | 72 | 78 | 91 | 79 |
| QIAGEN N.V. | 68 | 82 | 70 | 66 | 86 | 65 | 73 |
| Agilent Technologies Inc. | 73 | 73 | 75 | 77 | 59 | 57 | 69 |
| Bio-Rad Laboratories Inc. | 68 | 59 | 64 | 60 | 65 | 56 | 62 |
| PerkinElmer Inc. | 69 | 52 | 52 | 55 | 67 | 55 | 58 |
| Roche Diagnostics | 52 | 58 | 64 | 65 | 43 | 55 | 56 |
| BGI Genomics | 46 | 59 | 41 | 42 | 39 | 55 | 47 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Thermo Fisher Scientific
- Illumina Inc.
- QIAGEN N.V.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific | ✓ | ◐ | − | ◐ | ✓ | ✓ |
| Illumina Inc. | ◐ | ◐ | ✓ | ✓ | ✓ | ✓ |
| QIAGEN N.V. | ✓ | ✓ | ◐ | ◐ | ✓ | ◐ |
| Agilent Technologies Inc. | ✓ | ◐ | ✓ | ◐ | ◐ | − |
| Bio-Rad Laboratories Inc. | ◐ | − | ◐ | − | − | ◐ |
| PerkinElmer Inc. | ◐ | ◐ | − | − | ◐ | − |
| Roche Diagnostics | − | − | − | ◐ | − | ◐ |
| BGI Genomics | − | − | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Thermo Fisher Scientific84
2Illumina Inc.79
3QIAGEN N.V.73
4Agilent Technologies Inc.69
5Bio-Rad Laboratories Inc.62
6PerkinElmer Inc.58
7Roche Diagnostics56
8BGI Genomics47
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Thermo Fisher ScientificIllumina Inc.
Challenger2
Strong scale, closing on the leaders.
QIAGEN N.V.Agilent Technologies Inc.
Contender2
Focused players with pockets of strength.
Bio-Rad Laboratories Inc.PerkinElmer Inc.
Niche2
Specialists in a single segment or region.
Roche DiagnosticsBGI Genomics
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Omics Technology in North America, then scale across Omics Based Clinical Trials Market — a $162M beachhead inside a $2.33B market.
Beachhead (SOM)$162Mobtainable near-term
Serviceable (SAM)$945Mreachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion88 fit
Genomics
Best fit — highest urgency & budget in Omics Technology.
Economic buyer81 fit
Proteomics
Strong fit — clear ROI and a fast path to value.
End user68 fit
Metabolomics
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Omics Technology in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Clinical Trial Phase & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Application Area
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales46%
Partner / channel28%
Digital / self-serve20%
Marketplaces6%
Positioning & messaging
§GTM 2 · p.194 →For Omics Technology leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Omics Based Clinical Trials Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified38%
Sales qualified25%
Evaluation14%
Closed-won7%
$21.5KCAC
$116KLTV
5.4:1LTV : CAC
< 5 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Omics Based Clinical Trials Market is a resilient opportunity — $5.11B by 2033, compounding at 4.5%.
TAM · 2025$3.58Btoday
TAM · 2033$5.11Bforecast
CAGR4.5%2027–2033
Cumulative$38.7Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$5.11BTotal addressable market
SAM$1.95BServiceable available market
SOM$319MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →4.5% CAGR
Demand compounds through 2033, outpacing GDP across Omics Technology.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Omics Technology moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$5.11BLarge & growingTAM by 2033 at 4.5% CAGR
$1.95BServiceable nowreachable with today’s model
$319MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$3.98BBear2.9% CAGR
$5.11BBase4.5% CAGR
$6.53BBull6.0% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Clinical Trial Phase optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Omics Based Clinical Trials Market — a $9.57B market by 2033. Plan: grow share from 9.0% to 17.2%.
Market size · 2033$9.57Btotal addressable
Market CAGR7.7%2027–2033
Target share17.2%from 9.0% today
Revenue ambition$1.65Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 9.0% | 17.2% | On track |
| Revenue | $782M | $1.65B | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | Ahead |
| Gross margin | 35.6% | 42.0% | On track |
| Customer retention | 87.3% | 97.0% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Omics Technology
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Clinical Trial Phase capability
A defensible second engine — invest in Clinical Trial Phase to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Omics Technology share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Clinical Trial Phase
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $194M capacity & capability investment
- Greenlight bolt-on M&A in Clinical Trial Phase
- Authorise North America expansion plan
- Fund R&D program for Omics Technology leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossBehind
- Input-cost & supply riskOn track
- Regulatory / policy changeAt risk
- Execution & talentAhead
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Omics Based Clinical Trials Market conversation — a $954M market you can size, segment and defend in minutes.
Market size · 2033$954Mtotal opportunity
Growth9.9%CAGR to 2033
Addressable buyers1,489+accounts in scope
Typical ROI5.4×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Omics Technology
Goal Grow share in Omics Technology
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.4×return on cost, year one
< 3 mopayback period
$70K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
Thermo Fisher ScientificIllumina Inc.QIAGEN N.V.Agilent Technologies Inc.Bio-Rad Laboratories Inc.PerkinElmer Inc.Roche DiagnosticsBGI Genomics+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Omics Based Clinical Trials Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Omics Based Clinical Trials Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Omeprazole Sodium for Injection Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportOmeprazole Sodium API Market
Market size, share, segmentation and regional forecast.
$3.7B market · 2025 base year
View reportOmeprazole Enteric-coated Capsules Market
Market size, share, segmentation and regional forecast.
$2.1B market · 2025 base year
View reportOmeprazole API Market
Market size, share, segmentation and regional forecast.
$5.3B market · 2025 base year
View reportOmega-7 Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportOmega-3 Supplements Market
Market size, share, segmentation and regional forecast.
$901M market · 2025 base year
View reportOmega 3 Prescription Drug Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportOmega-3 Ingredient for Pharmaceutical Market
Market size, share, segmentation and regional forecast.
$3.8B market · 2025 base year
View reportOmega-3 Fish Oil Supplements Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportOmega-3 Ethyl Ester Capsule Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportOmalizumab Monoclonal Antibody Biosimilars Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportOmalizumab for Injection Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.